Bronchiectasis Adult Clinical Trial
Official title:
Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls
Verified date | July 2017 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Analysis of mucus, mucin and DNA concentration, MUC5B/5AC ratio, rheology, osmotic pressure, cohesion and nucleotides in sputum on 30 individual samples of good quality in healthy individuals and those with bronchiectasis. (60 total)
Status | Completed |
Enrollment | 30 |
Est. completion date | June 27, 2017 |
Est. primary completion date | June 27, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Participants who meet all the following criteria are eligible for the study: - Written informed consent - Bronchiectasis patients: Available CT of the chest that shows evidence of dilated airways fulfilling radiographic criteria for bronchiectasis in more than one lobe and chronic cough. Participants who meet any of the following criteria will not be eligible for the study: - Healthy individuals: A history of lung disease, current asthma symptoms or medication use, premature birth (<37 week gestation), a history of lung disease of infancy, or neurological or cardiovascular illness, current smoker or a history of smoking tobacco products. - Bronchiectasis patients: Premature birth (<37 week gestation), a history of lung disease of infancy, or neurological or cardiovascular illness. - Younger than 18 years of age |
Country | Name | City | State |
---|---|---|---|
United States | Center for Environmental Medicine Asthma and Lung Biology | Chapel Hill | North Carolina |
United States | Marsico Research Institure at Meadowmont | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mucus concentration (% solids) | The percentage of solid content of sputum (an index of hydration) will be calculated my measuring the wet to dry weight ratio using a microbalance (mean percent solids ± standard deviation). | 6 months | |
Secondary | Biophysical properties of mucus by rheology | The rheological properties of the sputum will be assayed by macro-rheology (cone and plate) and microbead rheology. Macro-rheology provides measures of the viscosity (median log viscosity in Pascal (range)) and elasticity (median log elasticity in Pascal (range) of the sputum. Microbead rheology is performed by analyzing the diffusive motion of embedded 1µm tracer particles (6). The primary outcome measure from microbead rheology will be the mean square displacement MSD(Mean squared displacement) (median MSD cm2 s-1 (range)). | 6 months | |
Secondary | Mucin composition by mass spectroscopy | We will use mass spectroscopy to determine the relative abundance of the two major polymeric mucin proteins, MUC5B(Mucin type 5B)and MUC5AC(Mucin type 5AC), which are responsible for the viscoelastic properties of mucus. | 6 months | |
Secondary | Sputum extracellular nucleotide analysis | Sputum adenosine and adenine nucleotides will be ethenoderivatized and measured by HPLC(High performance liquid chromatography) analysis (7) (median nucleotide concentration in µg/ml (range)). | 6 months | |
Secondary | Osmotic Pressure | The osmotic pressure of the mucus will be assessed by placing an aliquot of mucus onto an osmometer with a 10kDa (10 kilodaltons) molecular weight polyethersulfone membrane (Millipore) separating the test chamber and reference chamber filled with PBS (phosphate-buffered saline) (mean osmotic pressure in Pascal ± standard deviation). | 6 months | |
Secondary | Total mucin concentration | Mucins will be quantitated using sepharose CL2B(Cross-linked derivative of Sepharose 2B) UPLC(Ultra performance liquid chromatography) coupled to an Optilab interference refractometer with a filter at 680 nm and parallel flow chambers for solvent and the solution (mean mucin concentration (µg/ml) ± standard deviation) (4). With this approach, we will ensure that the solute is at full Donnan equilibrium with the solution within the context of gel chromatography, which creates an accurate equilibration of solute and solvent. This procedure also separates the mucins from contaminating proteins, allowing the mucins to be isolated for biochemical studies. DNAse can be added if significant DNA is present. | 6 months | |
Secondary | polymeric DNA concentration | The quantification of free DNA will be performed using the DNA Quant-iT PicoGreen assay (Molecular Probes, Inc., Eugene, OR, USA), which utilizes an ultra-sensitive fluorescent nucleic acid stain for quantitating double-stranded DNA (median log DNA concentration (µg/ml) (range)). | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04142827 -
The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX)
|
N/A | |
Recruiting |
NCT06093191 -
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
|
Phase 4 | |
Recruiting |
NCT06393257 -
Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis
|
N/A | |
Not yet recruiting |
NCT04509661 -
Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation
|
Phase 4 | |
Recruiting |
NCT06017739 -
Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis
|
N/A | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Recruiting |
NCT03715322 -
Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
|
Phase 3 | |
Recruiting |
NCT03696290 -
Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis
|
Phase 2 | |
Not yet recruiting |
NCT05068518 -
The Role of Airway Microbiota on Clinical Phenotypes and Disease Severity in Bronchiectasis
|
||
Recruiting |
NCT04658277 -
Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations
|
N/A | |
Completed |
NCT04744220 -
Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis
|
N/A | |
Completed |
NCT05764343 -
The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases
|
N/A | |
Recruiting |
NCT05582798 -
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function
|
Phase 4 | |
Not yet recruiting |
NCT04987827 -
Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients
|
||
Recruiting |
NCT03791086 -
The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
|
||
Completed |
NCT04234789 -
Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis
|
N/A | |
Recruiting |
NCT04865861 -
The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
|
||
Completed |
NCT04742270 -
Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis)
|
N/A | |
Recruiting |
NCT05330637 -
Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
|
||
Completed |
NCT05989360 -
The Utility of Lung Clearance Index in Ethnic Groups and in Disease
|
N/A |